TTX-MC138

TransCode Starts Phase 2a Trial for TTX-MC138

BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...

By cGxPwire Editor
May 28, 2026

.Clinical Bio-Pharma

TransCode Reports Positive Phase 1a Results for TTX-MC138 in Metastatic Cancer

BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...